Loading
Axogen, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wendell Amy McBride, was filed 08 Sept 2023.
Axogen, Inc.: what insiders have been doing
Axogen, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). In the past year (20 October 2025 to 20 October 2026), 46 filings came from 15 insiders.
No insider bought on the market over the period, while 10 insiders filed 14 sales totalling €8.6M. Biggest ticket of the year: €2.8M, sold by Began Marc A and made public on 12 August 2026 (0.12% of market cap).
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 46 filings, this issuer sits above that mark. Over the whole record (from 2021), the tally stands at 3 purchases and 37 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 225.2 m USD and net income of -15.7 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
212
Thresholds
n/a
Buy Volume
€174,594
3 ops. · all time
Sell Volume
€10M
37 ops. · all time
Who traded when
BuySaleAmy McBride Wendell4 sales
William P. Burke4 sales
Marc A. Began3 sales
Dale Michael d2 sales
Erick Wayne DeVinney2 sales
John Johnson2 sales
+6 other insiders
Since the insiders bought
- +123.7%Entry US$5.82 · Close at T+365 US$13.02
- +98.1%Entry US$6.39 · Close at T+365 US$12.66
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Axogen, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$53.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,143 of 26,364 companies
36.3
score / 100
Value33
Quality40
FCF yld-0.2%
Earn yld-0.8%
EV/EBITDA·
ROE-18%
Gross mgn74%
Net mgn-7.0%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$37.11
Analyst consensus
12 analystsStrong buy
US$48.00Target US$53.67(+45%)US$58.00
Income statement
RevenueUS$225.2M
Gross profitUS$167.4M74% margin
EBITDAUS$507k0% margin
Net income-US$15.7M-13.4% margin
Valuation
PER (forward)51.5x
P/Book7.8x
Beta1.17
Balance sheet & cash
Market capUS$2.2B
Total debtUS$67.6M
Free Cash Flow-US$4.8M
Debt / Equity8%
Profitability & ownership
ROE-18.2%
ROA-3.1%
% insiders2.0%
% institutions98.6%
Last declaration on 4 September 2026
Declarations212 total
3,500 shares@ US$49.6970.0067% mcap39.9% of flowCommon StockSEC:0000805928-26-000101:0
13,353 shares@ US$48.4230.025% mcap44.7% of flowCommon StockSEC:0000805928-26-000098:1
13,353 shares@ US$14.850.0077% mcap13.7% of flowCommon StockSEC:0000805928-26-000098:0
67,500 shares@ US$8.160.021% mcap12.4% of flowCommon StockSEC:0000805928-26-000099:0
67,500 shares@ US$47.3450.12% mcap72.2% of flowCommon StockSEC:0000805928-26-000099:1
13,353 shares@ US$48.220.025% mcap100.0% of flowCommonSEC144:0001950047-26-007960
14,150 shares@ US$45.2980.025% mcap79.1% of flowCommon StockSEC:0000805928-26-000096:0
67,500 shares@ US$46.430.12% mcap100.0% of flowCOMMONSEC144:0001950047-26-007883
14,150 shares@ US$44.350.024% mcap100.0% of flowCommonSEC144:0001950047-26-007808
18,867 sharesCommon StockSEC:0000805928-26-000078:0
14,150 sharesCommon StockSEC:0000805928-26-000079:0
14,150 sharesCommon StockSEC:0000805928-26-000080:0
14,150 sharesCommon StockSEC:0001400568-26-000013:0
14,150 sharesCommon StockSEC:0001410781-26-000006:0
14,150 sharesCommon StockSEC:0000805928-26-000076:0
14,150 sharesCommon StockSEC:0000805928-26-000077:0
1,647 shares@ US$14.850.0009% mcap1.7% of flowCommon StockSEC:0001400568-26-000009:0
1,647 shares@ US$42.600.0027% mcap4.8% of flowCommon StockSEC:0001400568-26-000009:1
4,000 shares0Common StockSEC:0000805928-26-000047:0
6,363 shares0Common StockSEC:0000805928-26-000048:0
33,780 shares0Common StockSEC:0000805928-26-000043:0
33,780 shares0Common StockSEC:0000805928-26-000042:0
17,453 shares0Common StockSEC:0000805928-26-000038:0
17,500 shares0Common StockSEC:0000805928-26-000032:0
25 of 212 declarations
About Axogen, Inc.
Axogen, Inc. is a United States-based medtech company listed on the NASDAQ market (United States) and focused on peripheral nerve regeneration and repair. Rather than competing as a broad pharmaceutical player, Axogen operates in a specialized surgical niche: restoring peripheral nerve function after traumatic injury or surgical damage. The company was incorporated in Minnesota and is headquartered in Florida, with processing, warehousing, and distribution facilities in Ohio and Texas. Its geographic footprint is therefore largely U.S.-centric, and the company generates substantially all of its revenue from customers in the United States. ([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm))
Axogen’s business model centers on the science, development, and commercialization of technologies used for peripheral nerve regeneration and repair. Its core product portfolio includes Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. These products address different steps in nerve surgery, from bridging nerve gaps to protecting repaired nerves and supporting soft tissue management. The company reports as a single operating segment, which underscores its highly focused strategy and its concentration on one clinical category rather than multiple end markets. ([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm))
Read moreShow less
From a competitive perspective, Axogen is positioned as a category specialist in a market that remains relatively underpenetrated but increasingly validated by clinical and reimbursement progress. Its long-term opportunity depends on surgeon adoption, payer coverage, and continued clinical acceptance of peripheral nerve repair as a standard of care. In 2025, Axogen highlighted an expansion in commercial coverage and reimbursement for peripheral nerve repair using synthetic conduits and allografts, an important indicator of market development and a potential driver of future utilization. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/02/24/3243354/0/en/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results.html))
Recent company milestones have been especially significant. In November 2024, the FDA accepted the filing of Axogen’s BLA for Avance® Nerve Graft and set a PDUFA goal date of September 5, 2025. On December 3, 2025, the FDA approved the BLA, marking a major regulatory inflection point for the company. In January 2026, Axogen completed an upsized public offering that generated $133.3 million in net proceeds; a portion of those funds was used to fully repay and terminate its Oberland loan facility, strengthening the balance sheet. For investors, Axogen represents a focused U.S. NASDAQ-listed healthcare story with a meaningful regulatory catalyst, a specialized product franchise, and a growing reimbursement backdrop. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/08/05/3127191/0/en/Axogen-Inc-Reports-Second-Quarter-2025-Financial-Results.html))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
